ABVX
Abivax S.A.NASDAQHealthcare$118.37+2.96%ClosedMarket Cap: $7.76B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
15.49
P/S
0.00
EV/EBITDA
-30.23
DCF Value
$8.20
FCF Yield
-2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-165.2%
ROA
-60.1%
ROIC
-48.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $-2.0M | 151.1% | $-147.0M | $-222.1M | $-3.06 | — |
| FY 2025 | $0.00 | -Infinity% | $-240.7M | $-322.8M | $-4.65 | — |
| Q2 2025 | $2.0M | 100.0% | $-93.7M | $-100.8M | $-1.59 | — |
| Q4 2024 | $7.4M | 100.0% | $-133.0M | $-94.6M | $-1.50 | — |
| FY 2024 | $10.8M | 100.0% | $-173.0M | $-176.2M | $-2.80 | — |
| Q2 2024 | $3.4M | 100.0% | $-40.0M | $-40.8M | $-0.65 | — |
| Q4 2023 | $2.3M | 100.0% | $-92.5M | $-95.8M | $-1.98 | — |
| FY 2023 | $4.6M | 99.0% | $-127.4M | $-147.7M | $-3.43 | — |
| Q2 2023 | $2.2M | 100.0% | $-39.5M | $-52.0M | $-1.45 | — |
| Q4 2022 | $2.2M | 100.0% | $-38.8M | $-40.3M | $-1.81 | — |
| FY 2022 | $4.6M | 97.6% | $-64.8M | $-60.7M | $-3.18 | — |
| Q2 2022 | $2.2M | 100.0% | $-18.6M | $-29.6M | $-1.76 | — |